TABLE 1. Recurrence rates reported after curettage of giant cell tumors of bone.

Author	Year	Tumor Characteristics	Adjuvant Treatments	Number of Patients	Recurrence Rate
Capanna et al.3	1990		none	280	45%
Shih et al.33	1998		none*	22	0%
Richardson et al.32	1998		none	16	0%
Blackley et al.29	1999		none	59	12%
Durr et al.10	1999		none	7	43%
Saglik et al.41	1999		none	21	33%
Trieb et al.16	2001		none	14	21%
Turcotte et al.40	2002		none	~50	17%
Khan et al.30	2004	distal radius only	none	23	17%
Prosser et al.31	2005	stage 1 &2	none	61	7%
		stage 3	none	52	29%
		recurrent	none	29	34%
Capanna et al.3	1990		PMMA	187	19%
O'Donnell et al.12	1994		PMMA	49	24%
Bini et al.23	1995		PMMA	38	8%
Saglik et al.41	1999		PMMA	6	0%
Wada et al.42	2002		PMMA	15	7%
Turcotte et al.40	2002		PMMA	62	19%
McDonald et al.5	1986		phenol	80	34%
Capanna et al.3	1990		phenol	147	19%
Durr et al.10	1999		phenol	11	9%
Trieb et al.16	2001		phenol	12	25%
Turcotte et al.40	2002		phenol	37	19%
Su et al.15	2004		phenol	56	18%
Capanna et al.3	1990		cryotherapy	20	19%
Sheth et al.19	1995	distal radius only	cryotherapy	12	25%
Malawer et al.17	1999	primary	cryotherapy	86	2.3%
		recurrent	cryotherapy	16	37.5%
Turcotte et al.40	2002		cryotherapy	10	0%
Zhen et al.21	2004		Zinc Chloride	92	13%
Capanna et al.3	1990		phenol+PMMA	33	3%
Ghert et al.43	2002		phenol+PMMA	47	13%
Lackman et al.11	2005	stage 2 & 3 only	phenol+PMMA	63	6%
O'Donnell et al.12	1994		phenol+PMMA	11	27%
Saiz et al. 14	2004		phenol+PMMA	40	13%
Ward and Li20	2002		H2O2+phenol+ electrocautery+ PMMA (in half)	24	8%

PMMA = polymethylmethacrylate cement.

^*"none" may include the use of a high speed burr, which some authors consider an adjuvant.